Showing results (11-20 of 389) with videos related to
Sort By:
Pageof 39
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 16, 2013
Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangementMasayuki Takeda, Isamu Okamoto, Kazuhiko NakagawaLung Cancer (Amsterdam, Netherlands)|February 24, 2015
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancerMasayuki Takeda, Isamu Okamoto, Kazuhiko NakagawaGan to Kagaku Ryoho. Cancer & Chemotherapy|June 23, 2009
[Cancer of unknown primary site-current status and future direction]Yasuko Ichikawa, Isamu Okamoto, Kazuhiko NakagawaJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinibMasayuki Takeda, Isamu Okamoto, Kazuhiko NakagawaCancer Management and Research|June 21, 2013
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatmentHiroyasu Kaneda, Takeshi Yoshida, Isamu OkamotoExpert Review of Anticancer Therapy|January 25, 2018
Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancerEiji Iwama, Yoichi Nakanishi, Isamu OkamotoRespiratory Investigation|May 17, 2018
Anticancer drug treatment for advanced lung cancer with interstitial lung diseaseKohei Otsubo, Isamu Okamoto, Naoki Hamada, et al.Investigational New Drugs|July 14, 2007
Amrubicin for non-small-cell lung cancer and small-cell lung cancerTakayasu Kurata, Isamu Okamoto, Kenji Tamura, et al.Lung Cancer (Auckland, N.Z.)|February 18, 2017
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancerMasayuki Takeda, Isamu Okamoto, Yasumasa Nishimura, et al.Investigational New Drugs|June 3, 2011
Reversible posterior leukoencephalopathy syndrome and trastuzumabHiroyasu Kaneda, Isamu Okamoto, Taroh Satoh, et al.Pageof 39